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Synthesizing Law for Synthetic Biology
Andrew W. Torrance*
I. INTRODUCTION
In his influential 2005 article Foundations for Engineering
Biology, Drew Endy, a professor in the Department of
Bioengineering at Stanford University and “one of synthetic
biology’s foremost visionaries,”1 described the considerable
promise and limitations of synthetic biology.2 On the optimistic
side of the ledger, it had already “been used to manipulate
information, construct materials, process chemicals, produce
energy, provide food, and help maintain or enhance human
health and our environment.”3 However, he also lamented that
“our ability to quickly and reliably engineer biological systems
that behave as expected remains quite limited.”4 In the ensuing
five years, synthetic biology has begun to realize its scientific
potential and has reached the public consciousness.
In November 2010, the seventh annual International
Genetically Engineered Machine (iGEM) competition will be
© 2010 Andrew W. Torrance.
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1. Jon Mooallem, Do-It-Yourself Genetic Engineering, N.Y. TIMES MAG.,
Feb. 14, 2010, at 40, 42.
2. Drew Endy, Foundations for Engineering Biology, 438 NATURE 449,
449 (2005).
3. Id.
4. Id.
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held at the Massachusetts Institute of Technology (MIT).5 It is
expected that roughly two thousand synthetic biologists,
organized into two hundred teams from dozens of countries,
will participate. Starting with identical kits of BioBrick™
standard DNA parts (BioBricks), which can be combined in a
manner analogous to Lego® bricks or even modified, teams will
compete with each other to create synthetic genes,
polypeptides, metabolic pathways, cells, and organisms that
will be eligible for prestigious prizes at these synthetic biology
Olympics. The Registry of Standard Biological Parts (the
Registry), hosted by MIT, provides these kits of BioBricks to
competitors and also requests that teams submit new or
modified BioBricks back into the Registry.6 Since its inception
in 2003,7 the Registry has received more than 12,000 DNA
sequences.8 By comparison, there are only about 20,000 genes
in the human genome.9
To illustrate the remarkable progress being made by
synthetic biology, consider a few of the winning projects at the
2009 iGEM competition. On November 2, 2009, thousands of
cheering synthetic biologists—mostly undergraduates with a
relatively modest formal background in biology—gathered
inside MIT’s Kresge Hall to watch a combined team of Spanish
students from the Universitat Politècnica de València and the
Universitat de València (Team València) present the project
that carried them to the finals. In a surprising turn of events,
Team València began performing jumping-jacks on the stage.
Yet, there was method in their strangeness. Soon, on a giant
screen behind the team members, a pixilated but recognizable
human figure appeared on a computer display and began
mirroring Team València’s calisthenics. However, this was no
ordinary computer display. It was an LEC, or light emitting
cell, display. The pixels on the computer screen were composed
5. See iGEM 2009 Main Page, http://2009.igem.org/Main_Page (last
visited Jan. 23, 2010) [hereinafter iGEM Main].
6. Welcome to the Registry of Standard Biological Parts,
http://partsregistry.org/Main_Page (last visited Feb. 4, 2010) [hereinafter
Welcome].
7. Id.
8. Registry of Standard Biological Parts Statistics Snapshot,
http://partsregistry.org/cgi/partsdb/Statistics.cgi (last visited Feb. 4, 2010)
[hereinafter Registry].
9. JAMES D. WATSON ET AL., MOLECULAR BIOLOGY OF THE GENE 139 (6th
ed. 2008).
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not of electronic or chemical components, but, rather, of living
cells. As described by Team València, “[e]ngineered yeasts able
to sense and respond to electrical signals are build [sic] (what
we call LEC). Thanks to a homemade device these LECs work
cooperatively in such a way that they are able to reproduce
images in movement, building up a ‘bio-screen’ for the first time
in history.”10 Team València had successfully created a living
computer screen composed of genetically engineered yeast
capable of responding precisely and efficiently in response to
human commands effectuated through electrical signals. For
their efforts, they won top awards in the categories of Best New
Application Area and Best Experimental Measurement, and
finished as Second Runner Up for the Grand Prize (that is, the
Biobrick Trophy).11
The team that did win the Grand Prize, from Cambridge
University, United Kingdom,12 also managed a remarkable feat
of biological engineering by designing and constructing several
artificial genes that will allow genetically engineered
eubacteria to detect and report environmental toxins by
changing color.13 These color sensors work with a “sensitivity
tuner” to allow reporting-via-color of both the presence of a
toxin as well as its concentration. They named the eubacterium
that will carry out this elegant task “E. chromi” (that is,
chromi—”of color”—rather than coli).14 Team Cambridge also
won the award for Best Environment Project.15 Rounding out
the top three teams, the First Runner Up was a team from the
Universität Heidelberg, Germany,16 which “developed and
successfully applied a synthesis method for synthetic
promoters,17 and a strategy for their rational design.”18

10. iGEM
2009
Team
Valencia
Home
Page,
http://2009.igem.org/Team:Valencia/home (last visited Jan. 24, 2010).
11. iGEM Main, supra note 5.
12. Id.
13. iGEM
2009
Team
Cambridge
Project
Page,
http://2009.igem.org/Team:Cambridge/Project (last visited Mar. 7, 2010).
14. Id.
15. iGEM Main, supra note 5.
16. Id.
17. Promoters are fundamental regions of DNA that modulate the
expression of genes (that is, gene function). BENJAMIN LEWIN, GENES IX 860
(2008) (“A promoter is a region of DNA where RNA polymerase binds to
initiate transcription.”).
18. iGEM
2009
Team
Heidelberg
Project
Page,

TORRANCE_MACROS_FINAL (DO NOT DELETE)

632

MINN. J. L. SCI. & TECH.

6/16/2010 2:16 PM

[Vol. 11:2

The fact that these synthetic biological creations were
designed and built by undergraduate students illustrates the
power and potential of synthetic biology. Unsurprisingly,
professional biologists, including academics and other medical
researchers, as well as commercial enterprises are also using
synthetic biology to design and develop new genes, gene
combinations, genomes, metabolic pathways, viruses, cells, and
organisms. The Registry makes BioBricks available not just to
participants in the iGEM competition, but to academic research
laboratories as well.19 Perhaps the most famous of these
products so far is artemisinin, a drug effective at treating
malaria. Amyris Biotechnologies has continued the research of
Jay Keasling, a University of California Berkeley biochemical
engineering professor, to produce a synthetic platform for
producing artemisinin.20 To accomplish this, Keasling and his
research team spliced together several genes from different
source organisms into the eubacterium E. coli to enhance
production of artemisinin.21 Using synthetic biology, Keasling
and his colleagues have “increased the amount of artemisinic
acid that each cell could produce by a factor of one million,
bringing down the cost of the drug from as much as ten dollars
for a course of treatment to less than a dollar.”22 Another
prominent goal to which synthetic biology is being applied is
the engineering of a synthetic cellulase enzyme capable of
efficiently converting cellulose from plant waste into simpler
sugars that could, in turn, be used in the inexpensive
production of renewable bio fuels. Both Amyris and another
biotechnology company, LS9, are currently using synthetic
biological techniques to pursue this potentially lucrative, and
socially useful, goal.23
The growing excitement surrounding the potential of
synthetic biology has now penetrated the public consciousness.
http://2009.igem.org/Team:Heidelberg/Project (last visited Jan. 18, 2010).
19. Welcome, supra note 6.
20. Michael Specter, A Life of Its Own, NEW YORKER, Sept. 28, 2009, at
56, 58.
21. Vincent JJ Martin et al., Engineering a Mevalonate Pathway in
Escherichia Coli for Production of Terpenoids, 21 NATURE BIOTECH. 796, 797
(2003).
22. Specter, supra note 20, at 58.
23. See Mooallem, supra note 1, at 42; Amyris - Our Products,
http://www.amyris.com/index.php?option=com_content&task=view&id=33&Ite
mid=300 (last visited Jan. 29, 2010).
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Though the field had already achieved considerable scientific
success and recognition, its public profile attained new heights
over the past year, as two of the most influential U.S.
magazines—The New Yorker and The New York Times
Magazine—both published feature articles about synthetic
biology within a five-month period.24
It is easy to understand the field’s appeal. Synthetic
biology offers an approach to, and technologies for, radically
altering the meaning of biology, as well as the meaning of
“alive.” By reimagining biology from the perspective of
engineers, computer programmers, and hackers, synthetic
biologists hope to move beyond the strictures imposed on genes,
cells, and organisms by eons of evolution by natural selection.
Furthermore, by emphasizing open standards for, and
relatively free sharing of, biological “parts,” making those parts
widely available to those both within and outside the biological
research establishment, and encouraging users of those parts to
alter, combine, and employ them in novel, unsupervised, and
unexpected ways, many synthetic biologists hope to create a
community of open source biology engineers and biohackers
capable of constructing anything from cellular computers to
self-constructing wooden houses.
This article examines how the law may adapt to the
challenges offered by synthetic biology. Part II provides an
overview of the science that underpins the field. Part III
analyzes how intellectual property law, particularly patent,
copyright, and trademark law, will accommodate some of the
unique features spawned by synthetic DNA. Part IV analyzes
the open innovation25 approach to innovation that has driven
the development of synthetic biology so significantly, and
examines a nascent attempt to enshrine open innovation
values, as well as concerns over biosafety,26 into law.
II. SYNTHETIC BIOLOGY
The current explosion of interest in synthetic biology is the
culmination of a century of biological efforts to control, change,

24. Mooallem, supra note 1; Specter, supra note 20.
25. Throughout this article, “open innovation” is intended to function as
an umbrella phrase that includes user, open, and collaborative innovation.
26. In this article, “biosafety” is intended to include both biosafety and
biosecurity.
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reengineer, and remake living systems at the molecular level.
From experiments on fruit fly genetics conducted by Thomas
Hunt Morgan in the “Fly Room” at Columbia University27 in
the 1910s and 1920s to the elucidation of DNA as a doublehelix of nucleic acids by James D. Watson and Francis Crick in
1953,28 knowledge of molecular biology and methods for genetic
manipulation improved at an accelerating pace, finally allowing
the “engineering” and “programming” of living cells and their
genomes. This allowed a conceptual break with the previous,
largely descriptive, molecular biology, and ushered in a new
paradigm of genetic manipulation at the molecular level.
A. GENETIC ENGINEERING
In the early 1970s, Stanley N. Cohen, a professor at
Stanford University School of Medicine, and Herbert Boyer, a
professor at the University of California, San Francisco,
developed a technique that revolutionized the field of biology.
Using a restriction endonuclease, Cohen and Boyer, assisted by
several colleagues, cut open a DNA plasmid from the
eubacterium, Escherischia coli, inserted foreign DNA into the
gap in the plasmid, and then sealed this foreign DNA into the
Their experiments
E. coli plasmid using DNA ligase.29
demonstrated that DNA from different sources could be
deliberately recombined into patterns distinct from those in
nature.30
The invention of “recombinant DNA” allowed cells and
organisms to be genetically engineered.31 In turn, it fostered
the creation of a new industry: biotechnology. Several years
after the initial demonstration of genetic engineering by Cohen
and Boyer, a human gene, somatostatin, was successfully
spliced into E. coli.32 As Sally Hughes has summarized, genetic
27. See WATSON, supra note 9, at 12–13.
28. See EVELYN FOX KELLER, THE CENTURY OF THE GENE 3 (2000).
29. Stanley N. Cohen et al., Construction of Biologically Functional
Bacterial Plasmids In Vitro, 70 PROC. NAT’L ACAD. SCI. U.S.A. 3240, 3240
(1973).
30. Id. at 3244.
31. Sally Smith Hughes, Making Dollars out of DNA: The First Major
Patent in Biotechnology and the Commercialization of Molecular Biology, 92
ISIS 541, 542 (2001).
32. E.g., Keiichi Itakura et al., Expression in Escherichia Coli of a
Chemically Synthesized Gene for the Hormone Somatostatin, 198 SCI. 1056,
1056 (1977).
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engineering offered “a simple method for isolating and
amplifying any gene or DNA segment and moving it with
controlled precision, allowing analysis of gene structure and
function in simple and complex organisms.”33 This simple
method has advanced genetic research immensely by allowing
direct manipulation of and experimentation on genomes.
Although genetic engineering began as a method for
introducing a single foreign gene into the natural genome of
another cell, the techniques it has engendered have grown
significantly in complexity and in their power to modify
existing cells and organisms. Within five years of the first
deliberate recombination of DNA, ambition for the field had
vaulted towards “the new era of ‘synthetic biology’ where not
only existing genes are described and analyzed but also new
gene arrangements can be constructed and evaluated.”34
Synthetic biology has since moved well beyond this early
conception of the field as one of rearranging genes. Now the
field envisions not just the redesign of existing organisms, but
even the de novo design and “programming” of genes and
organisms.
B. GENETIC PROGRAMMING
Numerous metaphors have been used to describe gene
function. The metaphor most congruent to the goals of
synthetic biology is the gene as algorithm. In this conception of
the gene, DNA encodes a set of instructions for carrying out
functions via biochemistry just as a computer program encodes
a set of instructions for carrying out functions via electricity.
Sir Francis Crick, one of the Nobel Prize-winning co-discoverers
of the specific chemical structure of DNA, observed that “DNA
makes RNA, RNA makes protein, and proteins make us.”35
French geneticists François Jacob and Jacques Monod
established that some genes encode biochemical products that,
in turn, regulate the expression of other genes.36 They proposed
that “the genome contains not only a series of blue-prints, but a
co-ordinated program of protein synthesis and the means of
33. Smith Hughes, supra note 31, at 542.
34. Waclaw Szybalski & Ann Skalka, Nobel Prizes and Restriction
Enzymes, 4 GENE 181, 181–82 (1978).
35. Francis Crick, On Protein Synthesis, 7 SYMP. SOC’Y FOR
EXPERIMENTAL BIOLOGY 139 (1958).
36. E.g., WATSON ET AL., supra note 9, at 561.
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controlling its execution.”37 James Bonner further elaborated
this metaphor, suggesting that organisms are constructed and
maintained by a “master programme constituted in turn of a
set of subprogrammes or subroutines,”38 each of which, in turn,
comprises “a list of cellular instructions or commands.”39
One of the guiding principles of synthetic biology is that
genes and cells can be programmed like computers. As Arjun
Bhutkar has described, “A primary objective of this nascent
research area is to create a programmable microorganism from
scratch.”40 Pregnant in this description is the bold assumption
that living organisms are capable of being programmed in a
manner analogous to programming computers. To be
programmable like a computer, an organism or cell would
probably have to possess at least some computer-like
characteristics, such as relative structural simplicity and
functional predictability. By contrast, if an organism or cell
were to exhibit structural complexity or functional
unpredictability, programming it would be difficult and would
not tend to yield consistent results. One approach synthetic
biology takes to ensure programmability is the deliberate
reengineering of biological parts and systems to make them
structurally simplified and functionally predictable.
C. BIOLOGY AS ENGINEERING
In 1958, Edward L. Tatum and George W. Beadle won the
Nobel Prize for Medicine.41 Their research on the fungus
Neurospora produced strong evidence that each gene controls
the synthesis of a specific enzyme.42 In his Nobel Prize
acceptance speech, Tatum suggested a future in which biology
would move beyond description and experimentation into
design and manipulation:

37. François Jacob & Jacques Monod, Genetic Regulatory Mechanisms in
the Synthesis of Proteins, 3 J. MOLECULAR BIOLOGY 318, 354 (1961).
38. JAMES BONNER, THE MOLECULAR BIOLOGY OF DEVELOPMENT 134
(1965).
39. KELLER, supra note 28, at 86.
40. Arjun Bhutkar, Synthetic Biology: Navigating the Challenges Ahead,
J. BIOLAW & BUS., Vol. 8, No. 2, 2005, at 19, 20.
41. Edward
Tatum
Biography,
http://nobelprize.org/nobel_prizes/medicine/laureates/1958/tatum-bio.html
(last visited Feb. 2, 2010).
42. WATSON ET AL., supra note 9, at 19.
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With a more complete understanding of the functioning and
regulation of gene activity in development and differentiation, these
processes may be more efficiently controlled and regulated, not only
to avoid structural or metabolic errors in the developing organism,
but also to produce better organisms.
. . . [Understanding the genetic code] may permit the improvement of
all living organisms by processes which we might call biological
engineering.43

The 1970s saw the limited implementation of Tatum’s
“biological engineering” (or “genetic engineering”), which has
since flowered into a sophisticated array of molecular biological
techniques commonly known as “biotechnology.” A group of
biologists now hope to take biology beyond conventional genetic
engineering into a future where biology and engineering
science merge into a new field called “synthetic biology.”
For biology to give rise to an engineering discipline of
synthetic biology, ethos, insights, and approaches from
engineering science may be necessary. First and foremost,
there exists a fundamental threshold question about the nature
of biological systems, such as genes, genomes, cells, and
organisms. Is biology impenetrably complex, unmanageably
complicated, and essentially unpredictable, or can biological
systems and their components be understood, manipulated,
and controlled to an extent sufficient to synthesize artificial
versions? The latter is a necessary prerequisite for the
successful adoption of engineering principles to biology and for
the creation of synthetic biology as an engineering discipline.
Drew Endy, one of the leading voices advocating synthetic
biology as a discipline, has portrayed this question as a
welcome challenge and suggested it can be resolved
empirically.44 In his 2005 manifesto for synthetic biology,
Foundations for Engineering Biology, Endy,45 forcefully and
optimistically outlines the major challenges and future of the
field.46 If biology is amenable to engineering, then engineering
science may offer a potentially powerful conceptual approach

43. Edward
Tatum
Nobel
Lecture,
http://nobelprize.org/nobel_prizes/medicine/laureates/1958/tatum-lecture.html
(last visited Feb. 2, 2010).
44. Endy, supra note 2, at 449.
45. Stanford University School of Medicine and School of Engineering
Department
of
Bioengineering
Faculty
Page,
http://bioengineering.stanford.edu/faculty/ (last visited Mar. 7, 2010).
46. Endy, supra note 2, at 449–53.
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necessary to the success of synthetic biology. As summarized by
Endy, this approach involves at least three general principles:
(1) standardization, (2) decoupling, and (3) abstraction.47 In the
biological context, standardization would involve “the
definition, description and characterization of the basic
biological parts, as well as standard conditions that support the
use of parts in combination and overall system operation.”48
Decoupling would decompose larger tasks into smaller tasks
more amenable to specialization and discrete completion; for
example, the design of a metabolic pathway composed of
multiple genes might be separated from the construction of the
individual genes and of the whole pathway.49 Abstraction would
comprise at least two steps: breaking a biological engineering
problem into hierarchical levels of complexity (“abstraction
hierarchies”) and redesigning the basic components of
engineered biological systems to simplify the construction and
deconstruction of such systems.50 In theory, implementation of
the engineering science approach could lead to the wide
availability of standard biological parts that could be combined
into biological devices, which, in turn, could be used to build
biological systems.51 Nevertheless, as important as this
engineering science approach may be, the ethos of open science,
and a concomitant distaste for intellectual property, represents
what may be an even more significant influence in the
development of synthetic biology.
III. PROPRIETARY SYNTHETIC BIOLOGY
Synthetic biology promises to challenge fields beyond
science and technology. It is sure to unsettle notions of how the
intellectual property laws should apply to biotechnological
inventions. Three ways in which synthetic biology may force
change to legal doctrine are discussed below. First, humandesigned DNA sequences, systems, cells, and organisms may
avoid criticisms about patents claiming “products of nature.”52
Second, synthetic DNA sequences may qualify for copyright

47.
48.
49.
50.
51.
52.

Id. at 450–52.
Id. at 450.
Id. at 451.
Id. at 451–52.
Id.
E.g., Diamond v. Chakrabarty, 447 U.S. 303, 313 (1980).

TORRANCE_MACROS_FINAL (DO NOT DELETE)

6/16/2010 2:16 PM

2010] SYNTHESIZING LAW FOR SYNTHETIC BIOLOGY

639

protection as “original works of authorship fixed in [a] tangible
medium of expression.”53 Third, synthetic biology may create
new routes to trademark protection of its resulting products
and services by enabling the routine inclusion in DNA
sequences (or other engineered biological structures) of
distinctive motifs capable of serving as legally effective
indications of source.
A. SYNTHETIC GENE PATENTS
Judge Learned Hand provided the legal basis for the
patenting of DNA. At about the same time as the birth of
modern genetics, Judge Hand decided Parke-Davis & Co. v. H.
K. Mulford & Co.,54 a case involving purified adrenaline.
Considering the issue of whether adrenaline—a known
chemical found in nature—could be patentable subject matter,
he found that, when the inventor had removed adrenaline
“from the other gland-tissue in which it was found . . . it
became for every practical purpose a new thing commercially
and therapeutically.”55 Thus, Judge Hand concluded, “That was
a good ground for a patent.”56 By the 1970s, advances in
biotechnology had allowed the nucleotide sequences of genes to
be determined. In 1971, the claim element “gene” appeared for
the first time, in U.S. Patent No. 3,710,511.57 In 1973, the first
patent issued with “DNA” as a claim element.58 By 1982,
specific nucleotide sequences coding for specific polypeptides
(that is, human chorionic somatomammotropin (claim 1) and
animal growth hormone (claim 4)) had been successfully
claimed in U.S. Patent No. 4,363,877,59 the first patent
claiming the nucleotide sequences of genes per se.60

53. 17 U.S.C. § 102 (2006).
54. Parke-Davis & Co. v. H. K. Mulford & Co., 189 F. 95 (C.C.S.D.N.Y.
1911), aff’d, 196 F. 496 (2d Cir. 1912).
55. Id. at 103.
56. Id.
57. See Procedures for Use of Genic Male Sterility in Production of
Commercial Hybrid Maize, U.S. Patent No. 3,710,511 (filed Apr. 21, 1971)
(issued Jan. 16, 1973).
58. See Diagnostic Method Utilizing Synthetic Deoxyrilionucleotide
Oligomer Template, U.S. Patent No. 3,755,086 (filed Feb. 9, 1971) (issued Aug.
28, 1973).
59. See Recombinant DNA Transfer Vectors, U.S. Patent No. 4,363,877
(filed Apr. 19, 1978) (issued Dec. 14, 1982).
60. See Gene Patents and Global Competition Issues, GENETIC
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After the Diamond v. Chakrabarty decision in 1980,61
patent applications and issued patents claiming DNA
sequences increased rapidly.62 Today, patenting DNA
sequences is routine. The USPTO Utility Examination
Guidelines state that “[a] patent on a gene covers the isolated
and purified gene but does not cover the gene as it occurs in
nature.”63 The phrase “[‘isolated DNA’] or a similar term (e.g.,
‘modified DNA’ or ‘purified DNA’) is widely used to distinguish
the claimed DNA from its naturally occurring counterpart, i.e.,
genomic DNA encoding [the same polypeptide].”64 Such claims
are “unquestionably patentable over the corresponding
products of nature,”65 although they must also satisfy criteria of
patentability other than being statutory patentable subject
matter.66
Despite the longstanding Parke-Davis ruling, some have
argued that DNA sequences should not constitute patentable
subject matter because they are derived from natural
(“genomic”) DNA sequences.67 Synthetic biology allows these
concerns to be avoided entirely. Genes constructed using
synthetic biological techniques will have their origins in human
imagination and will, thus, not be products of nature. Even if
the courts were to accede to the wishes of those opposing the
patent eligibility of genes isolated from natural genomic
sources,68 synthetic genes would remain patentable subject due
to their non-natural origins. In fact, opposition to gene patents
as products of nature would incentivize preferential investment
in research, development, and patenting of synthetic genes.

ENGINEERING & BIOTECH. NEWS, Jan. 1, 2006, available at
http://www.genengnews.com/articles/chitem.aspx?aid=1163.
61. Diamond v. Chakrabarty, 447 U.S. 303 (1980).
62. Andrew W. Torrance, Gene Concepts, Gene Talk, and Gene Patents, 11
MINN. J. L. SCI. & TECH. 157, 178 figs.1 & 2 (2010).
63. United States Patent and Trademark Office Utility Examination
Guidelines, 66 Fed. Reg. 1092, 1093 (Jan. 5, 2001).
64. Fish & Richardson P.C., Master Class™: Biotech Course Materials,
Vol. 1, pg. I-5 (May 11-12, 2005).
65. Fish & Richardson P.C., Master Class™: Biotech Course Materials,
Vol. 1, pg. I-5 (May 11-12, 2005).
66. See, e.g., In re Fisher, 421 F.3d 1365 (Fed. Cir. 2005).
67. See, e.g., Andrew W. Torrance, Patent Rights and Civil Wrongs: The
ACLU Lawsuit, BIO-IT WORLD, July 2009, available at http://www.bioitworld.com/comment/2009/07/06/ACLU-lawsuit.html .
68. See, e.g., id.
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Recent tumult regarding the patentability of isolated
human genes is likely to raise the prospective value of
synthetic genes. On May 12, 2009, the American Civil Liberties
Union (ACLU) filed a lawsuit to challenge the eligibility of
human genes for patent protection.69 As the complaint stated,
Every person’s body contains human genes, passed down to each
individual from his or her parents. These genes determine, in part,
the structure and function of every human body. This case challenges
the legality and constitutionality of granting patents over this most
basic element of every person’s individuality.70

The patents in question claimed specific mutations in
tumor suppressor genes BRCA1 (“BRCA1, early onset”) and
BRCA2 (“BRCA2, early onset”).71 A positive test result for these
tumor suppressor genes usually show a substantial increase in
risk of developing breast and ovarian cancers in one’s life.72 On
March 29, 2010, the court granted the ACLU summary
judgment that human genes constituted unpatentable subject
matter.73 The decision from the court was decisive:
The claims-in-suit directed to “isolated DNA” containing human
BRCA1/2 gene sequences reflect the USPTO’s practice of granting
patents on DNA sequences so long as those sequences are claimed in
the form of “isolated DNA.” This practice is premised on the view that
DNA should be treated no differently from any other chemical
compound, and that its purification from the body, using well-known
techniques, renders it patentable by transforming it into something
distinctly different in character. Many, however, including scientists
in the field of molecular biology and genomics, have considered this
practice a “lawyer’s trick” that circumvents the prohibitions on the
direct patenting of DNA in our bodies but which, in practice, reaches
the same result. . .. It is concluded that DNA’s existence in an
“isolated” form alters neither this fundamental quality of DNA as it
exists in the body nor the information it encodes. Therefore, the
patents at issue directed to “isolated DNA” containing sequences
found in nature are unsustainable as a matter of law and are deemed
unpatentable subject matter under 35U.S.C.§101.74

Myriad Genetics is highly likely to appeal this decision to
the Federal Circuit, with strong support from the many
69. Complaint, Ass’n for Molecular Pathology v. U.S. Patent and
Trademark Office, 2010 WL 1233416 (S.D.N.Y. 2010) (No. 09 Civ. 4515).
70. Id. at 1.
71. Id. at 2.
72. BRACAnalysis,
Frequently
Asked
Questions,
http://www.bracnow.com/faqs/#50 (last visited May 13, 2010).
73. Ass’n for Molecular Pathology v. U.S. Patent and Trademark Office,
No. 09 Civ. 4515, 2010 WL 1233416, at *51 (S.D.N.Y. Mar. 29, 2010).
74. Id. at *2.
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companies, universities, and other institutions who own
potentially valuable gene patents. A further appeal to the U.S.
Supreme Court is also likely, given the economic and public
health importance of this issue. What is certain is that this
stunning court decision has focused intense interest on the
potential synthetic biology holds for designing genes unlike
those “found in nature.” The promise of synthetic biology
represents an important new pathway to obtaining patent
rights that successfully claim DNA.
B. SYNTHETIC GENE COPYRIGHTS
A number of previous authors have discussed the
applicability of copyright law to DNA sequences.75 However,
none of these discussions were written with the benefit of
considering the recent explosion in the field of synthetic
biology. Even so, none of these authors conclusively reject the
copyrighting of DNA sequences. In light of how plausible these
authors appear to consider the copyrightability of non-synthetic
DNA, the case favoring copyrightability of synthetic DNA is a
fortiori.
Copyright protection applies to “original works of
authorship fixed in any tangible medium of expression, now
known or later developed, from which they can be perceived,
reproduced, or otherwise communicated, either directly or with
the aid of a machine or device.”76 Fixation can occur in any
“form, manner, or medium.”77 However, the mode of fixation
must be “sufficiently permanent or stable to permit it to be
perceived, reproduced, or otherwise communicated for a period
of more than a transitory duration.”78 Since DNA is composed

75. E.g., Tani Chen, Can a Biological Sequence Be Copyrighted?, INTELL.
PROP. & TECH. J., Mar. 2007, at 1; Duncan M. Davidson, Common Law,
Uncommon Software, 47 U. PITT. L. REV. 1037, 1104–05 (1986); Irving Kayton,
Copyright in Living Genetically Engineered Works, 50 GEO. WASH. L. REV. 191
(1982); Donna Smith, Comment, Copyright Protection for the Intellectual
Property Rights to Recombinant Deoxyribonucleic Acid: A Proposal, 19 ST.
MARY’S L.J. 1083, 1096–1108 (1988); James G. Silva, Copyright Protection of
Biotechnology Works: Into the Dustbin of History?, B.C. INTELL. PROP. & TECH.
F.,
Jan.
28,
2000,
http://www.bc.edu/bc_org/avp/law/st_org/iptf/articles/content/2000012801.html
.
76. 17 U.S.C. § 102 (2006).
77. H.R. REP. NO. 94-1476, at 52 (1976).
78. 17 U.S.C. § 101 (2006).
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of stable chemical nucleotides, DNA sequences should easily
meet this requirement. Furthermore, DNA possesses definite
sequences of nucleotides that can easily be determined,79 copies
of DNA may be synthesized routinely and in effectively
unlimited quantities,80 and molecular DNA has been known to
last for at least many thousands of years with its nucleotide
sequence intact.81 The authorship requirement might pose a
barrier to the copyrightability of genes and other DNA
sequences derived entirely from natural genomes. A challenge
would be posed by 17 U.S.C. §102, which provides that
“[c]opyright protection subsists . . . in original works of
authorship.”82 By analogy, someone other than the author could
not claim copyright protection for a preexisting manuscript
simply by discovering its existence.83 However, synthetic
biology can involve the design and construction of new, humandesigned DNA sequences. Here the synthetic biologist designs
the particular DNA sequence, and “writes” it when she
synthesizes the sequence.84 Since there is an author in this
case, such DNA sequences should qualify as “original works of
authorship.” Furthermore, although DNA sequences lack the
explicit statutory recognition as copyrightable subject matter
that computer software possesses, synthetic DNA sequences
may be eligible for copyright protection under the expansive
interpretation of “works of authorship” manifested by Congress
in the legislative history of the 1976 amendments to the
Copyright Act.85 Finally, DNA sequences can be “perceived,

79. See, e.g., F. Sanger et al., DNA Sequencing with Chain-Terminating
Inhibitors, 74 PROC. NAT’L ACAD. SCI. U.S.A. 5463 (1977).
80. See, e.g., 2 JOSEPH SAMBROOK & DAVID W. RUSSELL, MOLECULAR
CLONING: A LABORATORY MANUAL 8.4 (3d ed. 2001).
81. See, e.g., Eske Willerslev & Alan Cooper, Ancient DNA, 272 PROC. R.
SOC’Y B 3, 3–5 (2005).
82. 17 U.S.C. § 102 (2006).
83. Of course, non-authors may obtain copyright protection through
contractual means for works authored by others.
84. In fact, fixing a DNA sequence via more conventional tangible forms of
expression, such as writing the nucleotide sequence down on paper, may also
suffice.
85. See H.R. REP. NO. 94-1476, at 51 (1976) (“The history of copyright law
has been one of gradual expansion in the types of works accorded protection,
and the subject matter affected by this expansion has fallen into two general
categories. In the first, scientific discoveries and technological developments
have made possible new forms of creative expression that never existed before.
In some of these cases the new expressive forms—electronic music, filmstrips,
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reproduced, or otherwise communicated, either directly or with
the aid of a machine or device.”86 The genetic code of DNA is
well understood by biologists. DNA sequences are easily
reproduced.87 And, machines and routine laboratory methods
allow the specific nucleotides in DNA sequences to be
determined.88
There is no explicit mention of DNA sequences in 17 U.S.C.
§ 102, nor do any of the eight enumerated categories of
copyrightable subject matter obviously include DNA sequences.
There are, however, several significant respects in which DNA,
genes, arrays of genes, and genomes (not to mention their RNA
and polypeptide products) fit within the “literary works”
category,89 both generally and as computer programs. Like the
English alphabet of twenty-six letters, DNA is composed of an
alphabet of four nucleotide “letters”: A, T, G, and C.90 Triplets
of these nucleotide letters form “codons” that correspond to
specific amino acids. When strung together in a linear chain,
amino acids comprise polypeptides. A synthetic biologist can
“write” strings of nucleotides (for example, genes) in any
pattern she wishes. Some patterns of nucleotide letters could be
written to produce specifically desired linear chains of amino
acids. At a higher level of organization, a synthetic biologist
could compose arrays of multiple synthetic genes in particular
patterns to produce complex results inside and outside cells.
Literary works are defined in § 101 as “works . . . expressed in
words, numbers, or other verbal or numerical symbols or
indicia, regardless of the nature of the material objects . . . in
which they are embodied.”91 Nucleotides, DNA, RNA, genes,
amino acids, polypeptides, and proteins are certainly “indicia,”
and the letters used to denote nucleotides and amino acids, as
well as the codes used to denote genes may also qualify as
“verbal . . . symbols.” Furthermore, the statement “regardless
and computer programs, for example—could be regarded as an extension of
copyrightable subject matter Congress had already intended to protect, and
were thus considered copyrightable from the outset without the need of new
legislation.”).
86. 17 U.S.C. § 102.
87. See, e.g., SAMBROOK & RUSSELL, supra note 80, at 8.4–8.17.
88. See, e.g., Sanger et al., supra note 79, at 5463.
89. 17 U.S.C. § 102.
90. A similar molecule, RNA, is composed of adenine, uracil (instead of
thymine), guanine, and cytosine. The RNA alphabet is A, U, G, and C.
91. 17 U.S.C. § 101 (2006).
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of the nature of the material objects . . . in which they are
embodied”92 could certainly include DNA or its related
molecules.
Section 102 does not restrict eligibility for copyright
protection only to the seven enumerated categories. Rather, the
section introduces the enumerated categories with the phrase
“include[s] the following categories.”93 In the “Definitions”
section of the Copyright Act,
§ 101 explains that
“including . . . [is] illustrative and not limitative.”94 The House
Report accompanying the 1976 Copyright Act reinforce this
broad interpretation:
The use of the word “include,” as defined in section 101, makes clear
that the listing is “illustrative and not limitative,” and that the seven
categories do not necessarily exhaust the scope of “original works of
authorship” that the bill is intended to protect. Rather, the list sets
out the general area of copyrightable subject matter, but with
sufficient flexibility to free the courts from rigid or outmoded concepts
of the scope of particular categories.95

When considered in conjunction with the expansive phrase
in § 102, “any tangible medium of expression, now known or
later developed,”96 synthetic DNA sequences fit comfortably
within the category of “literary works.”97
In 1974, the National Commission on New Technological
Uses of Copyrighted Works (CONTU) issued a report
concluding that “computer programs, to the extent that they
embody an author’s original creation, are proper subject matter
of copyright.”98 The CONTU was careful to distinguish
copyrightable subject matter, such as creative expression in
computer software, from uncopyrightable subject matter, such
as “ideas, procedures, processes, systems, methods of operation,
concepts, principles, or discoveries.”99 Moreover, it emphasized
that “one is always free to make the machine do the same thing
as it would if it had the copyrighted work placed in it, but only

92.
93.
94.
95.
96.
97.
98.

17 U.S.C. § 101 (2006).
17 U.S.C. § 102.
17 U.S.C. § 101.
See H.R. REP. NO. 94-1476, at 53 (1976).
17 U.S.C. § 102.
Id.
NAT’L COMM’N ON NEW TECHNOLOGICAL USES OF COPYRIGHTED
WORKS, FINAL REPORT OF THE NAT’L COMM’N ON NEW TECHNOLOGICAL USES
OF COPYRIGHTED WORKS 1 (1978) [hereinafter NAT’L COMM’N].
99. Id. at 18 (citing 17 U.S.C. § 102 (b)).
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by one’s own creative effort rather than by piracy.”100 Formal
recognition of computer software as copyrightable subject
matter occurred in 1980, when Title 17 (the “Copyright Act”)
was amended to include explicit copyright protection for
computer software.101 Section 101 of the Copyright Act defines
“computer program” as “a set of statements or instructions to
be used directly or indirectly in a computer in order to bring
about a certain result.”102 Although there are some special
limitations on the exclusive rights conferred to owners of
copyrights on computer software,103 this form of expression is
now routinely protected by copyright.
Synthetic biology is largely based on a conception of genes,
cells, and organisms as programmable. In a measured version
of this conception, Endy has suggested that “synthetic biology
provides an opportunity to test the hypothesis that the
genomes encoding natural biological systems can be ‘rewritten,’ producing engineered surrogates that might usefully
supplant some natural biological systems.”104 However, as a
more ambitious articulation has portrayed it, “[a] primary
objective of [synthetic biology] is to create a programmable
microorganism from scratch,” 105 and it is increasingly possible
to “program living organisms in the same way a computer
scientist can program a computer.”106 Consequently, if
computer software is copyrightable, perhaps “biological
software” is, or ought to be, as well.
It is relatively easy for a human mind to understand the
“meaning” of a DNA sequence. Once a proper reading frame
has been determined for the sequence,107 one only has to
recognize triplets of nucleotides and assign corresponding

100. NAT’L COMM’N, supra note 98, at 21.
101. See H.R. REP. NO. 96-1307, pt. 1, at 23–24 (1980).
102. 17 U.S.C. § 101 (2006).
103. 17 U.S.C. § 117 (2006).
104. Endy, supra note 2, at 449.
105. Bhutkar, supra note 40, at 20.
106. The BioBricks Foundation, http://bbf.openwetware.org/ (last visited
Jan. 7, 2010).
107. LEWIN, supra note 17, at 860 (“A reading frame is one of three possible
ways of reading a nucleotide sequence. Each reading frame divides the
sequence into a series of successive triplets. There are three possible reading
frames in any sequence, depending on the starting point. If the first frame
starts at position 1, the second frame starts at position 2, and the third frame
starts at position 3.”).
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amino acids to each triplet. Thus, someone of modest skill in
genetics could examine a DNA sequence of 300 coding
nucleotides, in proper reading frame, and then determine the
specific 100 amino acid sequence of its corresponding
polypeptide. By contrast, it is much more difficult for one of
similar skill in computer software to understand the “meaning”
of either object code or source code. With respect to computer
software, both source code and object code are eligible for
copyright protection.108 Source code is a form of a computer
program expressed in a programming language understandable
to humans. Object code, by contrast, is a form of a computer
program expressed in binary (that is, “1s” and “0s”); object code
cannot generally be understood by the human mind. If object
code is eligible for copyright protection, then, a fortiori, so
should DNA sequences, which can be relatively easily
understood.
Rather than portray DNA sequences as analogous to
computer software, a synthetic biologist might consider DNA
sequences actually to be a form of computer software. A gene is
a set of instructions for producing a polypeptide.109 A cell (or
even an organism), via the molecules, metabolic pathways, and
signaling pathways it contains, acts in response to the set of
instructions encoded in its genes to carry out a certain result.
Thus, “a [gene encodes a] set of statements or instructions to be
used directly or indirectly in a [cellular] computer in order to
bring about a certain [metabolic or signaling] result.”110 Given
that one of the primary goals of synthetic biology is to engineer
cells and genes to become ever more like computers and
computer software, as synthetic biology succeeds in making
DNA appear more similar to computer software, DNA
sequences will likely move towards copyrightability by analogy
to computer software. Alternatively, if cells and organisms are
already computers and genes are already software, then DNA
sequences are already eligible for copyright protection.
Whether or not cells are computers and genes are
computer software is largely an empirical question. Endy offers
108. E.g., Apple Computer, Inc. v. Franklin Computer Corp., 714 F.2d
1240, 1248 (3d Cir. 1983), cert. dismissed, 464 U.S. 1033 (1984).
109. LEWIN, supra note 17, at 852 (“A gene is the segment of DNA
specifying a polypeptide chain . . . .”).
110. Cf. 17 U.S.C. § 101 (2006). The bracketed material is added to show
how DNA sequences can fit into the existing definition of computer software.
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a number of examples, including:
[a] DNA sequence that programmes a biofilm to take a photograph
and perform distributed edge-detection on the light-encoded image . . .
[a] DNA sequence that programmes any mammalian cell to count up
to 256 in response to a generic input signal . . . [and a] DNA sequence
that programmes any prokaryote to produce 25 gl-1 artemisinic
acid.111

However, rather than characterizing any of these examples
as science fiction or hopeful thinking, Endy notes that “each
application is physically plausible, or is the direct extension of
an already demonstrated result.”112 This suggests that
synthetic biology is well on the way towards cells as computers
and genes as computer software. The consequences for the
copyrightability of synthetic DNA sequences are significant.
Copyright law limits protection to works of authorship that
do not monopolize a particular function.113 If a DNA sequence
of a synthetic gene were to represent the only way of producing
an RNA or polypeptide with a particular function, then that
sequence would not likely possess strong copyright protection.
However, if multiple DNA sequences could produce the RNA or
polypeptide with a particular function, then any one individual
sequence would likely have much stronger copyright protection.
In addition, as long as a work of authorship is original, it
cannot infringe the copyright of another work of authorship,
even if the two works of authorship are identical. Thus, even a
copyright protecting a particular synthetic DNA sequence
would not prevent others from independently designing an
identical or similar DNA sequence. In other words, independent
invention of identical or similar synthetic DNA sequences
would act as a counterbalance to any monopoly rights conferred
on the first author. Copying would still constitute copyright
infringement, but independent invention would be permissible.
This would stand in stark contrast to the rights conferred by
patents claiming DNA sequences because the strict liability
regime of patent law does not relieve independent inventors
from liability.

111. Endy, supra note 2, at 449.
112. Id.
113. See 2 MELVILLE B. NIMMER & DAVID NIMMER, NIMMER ON COPYRIGHT
§ 2.01[A] (Matthew Bender, rev. ed., 2009).
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C. SYNTHETIC GENE TRADEMARKS
One of the technologies that enables synthetic biology is
DNA synthesis.114 It is technically routine, rapid, and
increasingly inexpensive to design a DNA sequence de novo and
then construct it nucleotide by nucleotide.115 Numerous
companies offer DNA synthesis as a service.116 Research into
“DNA printers” has already achieved notable technical
successes.117 Machines for synthesizing custom DNA with highfidelity are likely to become standard equipment in biological
laboratories (and perhaps even beyond) in the near future. In
addition to its many more scientific applications, DNA
synthesis allows one to design patterns or motifs within a
strand of DNA capable of serving as an indicator of source.
One of the purposes of a trademark or servicemark is to
alert consumers as to the source of the goods or services to
which the mark is connected.118 Furthermore, “[b]y identifying
the source of the goods, [trademarks] convey valuable
information to consumers at lower costs.”119 The Lanham Act
defines “trademark” expansively as “includ[ing] any word,
name, symbol, or device, or any combination thereof.”120 The
Supreme Court has interpreted the Lanham Act as describing
“the universe of things that can qualify as a trademark . . . in
the broadest terms.”121 The Court has stated, however, that
“[t]he functionality doctrine prevents trademark law, which
seeks to promote competition by protecting a firm’s reputation,
from instead inhibiting legitimate competition by allowing a
producer to control a useful product feature.”122

114. This process is sometimes referred to alternatively as “gene
synthesis.”
115. Mark Welch et al., Design Parameters To Control Synthetic Gene
Expression in Escherichia Coli, PLOS ONE, Sept. 2009, at 1, 1.
116. E.g., GENEART, http://geneart.com/english/index.html (last visited
January 26, 2010); GenScript USA Inc., http://genscript.com (last visited Jan.
26, 2010).
117. E.g., Yoshihide Hayashizaki & Jun Kawai, A New Approach to the
Distribution and Storage of Genetic Resources, 5 NATURE REVS. GENETICS 223,
223 (2004).
118. S. REP. NO. 79-1333, at 3 (1946).
119. Scandia Down Corp. v. Euroquilt, Inc., 772 F.2d 1423, 1429 (7th Cir.
1985), cert. denied, 475 U.S. 1147 (1986).
120. Lanham Act § 45, 15 U.S.C. §1127 (2006).
121. Qualitex Co. v. Jacobson Products Co., Inc., 514 U.S. 159, 163 (1995).
122. Id. at 164.

TORRANCE_MACROS_FINAL (DO NOT DELETE)

650

MINN. J. L. SCI. & TECH.

6/16/2010 2:16 PM

[Vol. 11:2

A specific pattern or motif spliced into a synthetic DNA
sequence could serve a trademark function if it identified the
source of that DNA. To avoid the restrictions of the
functionality doctrine, such a DNA trademark would best be
placed outside of the coding (or functional) portion of the DNA
sequence. Only human creativity would limit the patterns of
nucleotides that synthetic biologists might choose to
incorporate into a synthetic DNA sequence. To serve as an
indicator of source, relevant consumers would have to recognize
the pattern or motif intended to indicate source. Consumers of
synthetic DNA sequences, however, would certainly scrutinize
such sequences very carefully as a matter of course, and it
would be difficult for them not to notice a DNA trademark. As
the field of synthetic biology becomes more commercially
important, DNA trademarks are likely to play increasingly
important roles as indicators of source.
IV. OPEN SYNTHETIC BIOLOGY
It has long been widely assumed that technological
innovation was best spurred by either governmental funding or
property-like incentives, such as patents and copyrights. The
United States Constitution explicitly enables Congress “[t]o
promote the Progress of Science and useful Arts, by securing
for limited Times to Authors and Inventors the exclusive Right
to their respective Writings and Discoveries.”123 However, the
rise in importance of open source and free software, as well as
insight into the phenomena of user, open, and collaborative
innovation, has revealed an increasingly significant alternative
to proprietary models of innovation. Within the field of
synthetic biology, there are influential scientists, notably Drew
Endy, Tom Knight, and Randy Rettberg, who have vigorously
tried to push the field in the direction of open innovation.
A. OPEN INNOVATION
Lawrence Lessig has noted that, although “[g]etting more
progress is the constitutional aim of patents . . . the question
that must always be asked of any patent regime is whether we
have good reason to believe that patents have that effect.”124
Lessig doubts the veracity of the traditional proprietary model
123. U.S. CONST., art. I, § 8, cl. 8.
124. LAWRENCE LESSIG, THE FUTURE OF IDEAS 205 (2002).
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of innovation, concluding instead that “[t]he strongest
conclusion one can draw is that whatever benefit patents
provide (except in industries such as pharmaceutics), it is
small.”125 Eric von Hippel, the leading scholar on open and user
innovation, is similarly dubious, noting that “[s]tudies find that
innovators in many fields view patents as having only limited
value.”126 Moreover, “most innovators do not judge patents to be
very effective [in spurring innovation], and . . . the availability
of patent grant protection does not appear to increase
innovation investment in most fields.”127 Von Hippel has
warned that, “with a few exceptions, innovators do not think
that patents are very useful either for excluding imitators or for
capturing royalties in most industries,”128 and that “the
characteristics of present-day intellectual property regimes as
actually experienced by innovators are far from the [beneficial]
expectations of theorists and policy makers.”129 He notes a
growing realization “that intellectual property rights are bad
for innovation too in many cases.”130
An increasing body of empirical research supports the
hypothesis that intellectual property protection may harm,
rather than spur, technological innovation. More than two
decades ago, von Hippel reported that “empirical data seem to
suggest that the patent grant has little value to innovators in
most fields.”131 In 2004, Bessen and Hunt presented empirical
evidence that, “on average, as firms’ investments in patent
protection go up, their investments in research and
development actually go down.”132 And, in their descriptively
named book, Patent Failure, Bessen and Meurer offered the
following observation:
[I]t is not clear that the entry of imitators is necessarily detrimental
to innovation as in the canonical reward theory model. If firms can
obtain some rents even when competing against a limited number of

125.
126.
127.
128.
129.
130.
131.
132.
Patents
2004).

Id. at 206.
ERIC VON HIPPEL, DEMOCRATIZING INNOVATION 10 (2005).
Id. at 112.
Id. at 84.
Id. at 112.
Id.
ERIC VON HIPPEL, THE SOURCES OF INNOVATION 48–51 (1988).
James Bessen & Robert M. Hunt, An Empirical Look at Software
(Federal Reserve Bank Of Philadelphia, Working Paper No. 03-17/R,
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other firms, then competition might actually increase innovation.133

Their results “suggest that much innovation is not
dependent on patenting.”134 They lament that “innovators have
grown frustrated with the failings of the American patent
system.”135 The authors also minimize the actual effect the
patent system has on innovation, arguing “patents are neither
the only nor even the most important means of encouraging
innovation. On average, patents make a rather small
contribution in this regard.”136 In 2009, an experimental study
that directly compared proxies of innovation, productivity, and
social utility in a patent system, a combination patent/open
source system, and a commons, found that the commons
outperformed the proprietary systems in every category
examined, and by statistically significant amounts.137
Moser has presented historical evidence showing that, at
least during the nineteenth century, countries with patent
systems did not experience significantly greater rates of
technological innovation than countries without patent
systems.138 The conclusion that Bessen and Meurer make is
damning:
Our empirical analysis indicates that the patent system provides
little innovation incentive to most public firms; these are the firms
that perform the lion’s share of R&D. So it seems unlikely that
patents today are an effective policy instrument to encourage
innovation overall.139

Heller and Eisenberg have long suggested that too much
patenting may result in an inefficient “tragedy of the
anticommons.”140 Bessen and Meurer concur, noting that “our
evidence implies that patents place a drag on innovation.
Without this drag, the rate of innovation and technological
progress might have been even greater, perhaps much
133. JAMES BESSEN & MICHAEL J. MEURER, PATENT FAILURE: HOW
JUDGES, BUREAUCRATS AND LAWYERS PUT INNOVATORS AT RISK 89 (2008).
134. Id. at 90.
135. Id. at 2.
136. Id. at 118.
137. Andrew W. Torrance & Bill Tomlinson, Patents and the Regress of
Useful Arts, 10 COLUM. SCI. & TECH. L. REV. 131, 160–62 (2009).
138. Petra Moser, How Do Patent Laws Influence Innovation? Evidence
from Nineteenth-Century World Fairs 24–33 (NBER Working Paper Series,
Working Paper No. 9909, 2002).
139. BESSEN & MEURER, supra note 133, at 216.
140. See, e.g., Heller & Eisenberg, Can Patents Deter Innovation? The
Anticommons in Biomedical Research, 280 SCI. 698, 698–701 (1998).
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greater.”141 Josh Lerner, conducting an empirical analysis of
patent reforms in sixty countries over 150 years, even noted a
modest negative correlation between the strengthening of a
country’s patent system and patenting activity by domestic
companies.142
These results are inconsistent with the traditional
assumption that the availability of intellectual property
protection spurs technological innovation. Yochai Benkler have
noted,
however,
that
“[i]ncreasing
patent
protection . . . increases the costs that current innovators have
to pay on existing knowledge more than it increases their
ability to appropriate the value of their own contributions,”143
and that patents may lower, rather than raise, rates of
productivity.144 Yochai and Benkler have instead proposed that
“commons-based strategies” may spur rates of innovation in
fields such as software, agriculture, and drug development
more than proprietary systems.145 Open biology and open
synthetic biology represent non-proprietary modes of
biotechnological innovation.
B. OPEN BIOLOGY
There is a strong ethos in the nascent synthetic biology
community in favor of maintaining open standards for and free
availability of standardized biological parts. Although patent
protection has traditionally been one of the economic pillars of
the pharmaceutical and biotechnology industries, “open source
biology” appears to be maintaining a strong lead over more
proprietary approaches to synthetic biology innovation. One
reason for this relative openness may be the academic
backgrounds of some influential synthetic biologists. For
example, the troika most responsible for the BBF and the
iGEM competition came to the field biology from a background
in engineering and computer science: Drew Endy received his
undergraduate degree in civil engineering;146 Tom Knight is a
141. BESSEN & MEURER, supra note 133, at 146.
142. YOCHAI BENKLER, THE WEALTH OF NETWORKS 39 (2006) (citing Josh
Lerner, Patent Protection and Innovation Over 150 Years 2 (Nat’l Bureau Of
Econ. Research, Working Paper No. 8977, 2002)).
143. YOCHAI BENKLER, THE WEALTH OF NETWORKS 39 (2006).
144. Id. at 49–50.
145. Id. at 317–55.
146. Mooallem, supra note 1, at 44.
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Senior Scientist at the Massachusetts Institute of Technology
(MIT) Computer Science and Artificial Intelligence
Laboratory;147 and Randy Rettberg is an electrical engineer and
computer scientist.148 The origins of the open source philosophy
lie within the computer software community.
Open source software differs markedly from proprietary
software. Open source software involves “computer source code
publicly available for licensees to use, modify, and redistribute,
provided that these licensees make their enhancements
available to others on the same terms.”149 The Open Source
Initiative (OSI), a prominent institution in the open source
community, has stated that software may qualify as open
source if distributed under a license conforming to the Open
Source Definition (OSD).150 Among the requirements of the
OSD are free redistribution, availability of source code, free
redistribution of derivative works, non-discrimination against
potential users or fields of use, and technology neutrality.151 In
an alternative conception proposed by Steven Weber, open
source software must comply with three conditions: (1) “[the
s]ource code must be distributed with the software or otherwise
made available for no more than the cost of distribution,” (2)
“[a]nyone may redistribute the software for free, without
royalties or licensing fees to the author;” and (3) “[a]nyone may
modify the software or derive other software from it, and then
redistribute the modified software under the same terms.”152
By any objective measure, open source software has been an
influential and successful model for producing valuable
software. The Linux operating system, the Apache web-server,
and the mySQL database system all demonstrate the efficacy of
the open source model of software design.153
Biology has seen several previous attempts at using the
open source approach. Led by biologist Richard Jefferson,

147. Id.
148. Id.
149. Donna M. Gitter, Resolving the Open Source Paradox in
Biotechnology: A Proposal for a Revised Open Source Policy for Publicly
Funded Genomic Databases, 43 HOUS. L. REV. 1475, 1476 (2007).
150. Open Source Initiative, http://opensource.org/ (last visited Jan. 15,
2010).
151. Id.
152. STEVEN WEBER, THE SUCCESS OF OPEN SOURCE 5 (2004).
153. Id. at 6.
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CAMBIA (derived from the Spanish verb cambiar, meaning “to
change”), a non-profit biotechnology research organization,
began as an attempt to develop open source, instead of
proprietary, biotechnology platforms for the genetic
modification of crops that would avoid patent infringement.154
CAMBIA’s BiOS (Biological Innovation for Open Society)
initiative explicitly aimed to duplicate the success of nonproprietary software development:
Similar to the ethos of the Free Software movement, the BiOS
Initiative is not about cheap or free stuff, either pharmaceuticals or
food. It’s about creating the freedom to innovate based on what has
come before, and the freedom to deliver the fruits of such innovation
with few constraints.155

The International HapMap Project (IHMP) represents
another biological science initiative modeled after the successes
of open source software. IMHP is a “partnership of scientists
and funding agencies from Canada, China, Japan, Nigeria, the
United Kingdom, and the United States to develop a public
resource that will help researchers find genes associated with
human disease and response to pharmaceuticals.”156 The
HapMap (or map of haplotypes) “is a catalog of common genetic
variants that occur in human beings.”157 The IHMP is
attempting to create a public domain database of haplotypes by
encouraging researchers not to patent their research, but,
instead, to contribute their haplotype data freely to the IHMP
genetic database. By “making this information freely available,
the [IHMP] will help biomedical researchers find genes
involved in disease and responses to therapeutic drugs.”158
Researchers do not require licenses to gain access to the IHMP
database, where data “can be downloaded with minimal

154. Cambia
–
Enabling
Innovation,
http://www.cambia.org/daisy/cambia/home.html (last visited Feb. 26, 2010).
155. THE CAMBIA BIOS INITIATIVE, BIOLOGICAL INNOVATION FOR OPEN
SOCIETY: IMPLEMENTATION PHASE 2006 – 2008 7 (2006), available at
http://www.bios.net/daisy/bios/2029/version/default/part/
AttachmentData/data/BiOS%20Initiative%20Phase%202006-2008.pdf.
156. International HapMap Project Home Page, http://www.hapmap.org/
(last visited Feb. 26, 2010).
157. International
HapMap
Project,
What
is
the
HapMap?,
http://hapmap.ncbi.nlm.nih.gov/whatishapmap.html.en (last visited Feb 26,
2010).
158. International
HapMap
Project,
About
the
HapMap,
http://hapmap.ncbi.nlm.nih.gov/thehapmap.html.en (last visited Jan. 15,
2010).
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constraints.”159 Although one of the goals of the IHMP is to
minimize hindrances on genetic research caused by patents, it
does not oppose patents claiming haplotypes “as long as this
action does not prevent others from obtaining access to data
from the [IHMP].”160
Another organization, the Tropical Diseases Initiative
(TDI), has been organized around the principles of open source
biology. The TDI was founded to spur medical research into
treatments for tropical diseases that devastate poor and
vulnerable populations in developing countries, focusing
especially on diseases that have attracted little research and,
as a result, development of fewer drugs to treat them.161 As
with the IHMP, the TDI has acknowledged an important role
for the patent system in spurring medical research, conceding
that “patent incentives and commercial pharmaceutical houses
have made Western health care the envy of the world.”162
Furthermore, proponents of the TDI have lamented that “[t]o
date, open-source methods have made little headway beyond
software.”163
C. OPEN SYNTHETIC BIOLOGY
In the realm of synthetic biology, two interrelated
institutions have taken the lead in promoting the ethos of open
biology: the BioBricks Foundation (BBF) and the iGEM
competition. The BBF is a non-profit foundation founded by
synthetic biologists at MIT, Harvard, and University of
California, San Francisco.164 Its stated mission is to promote
“the development and responsible use of technologies based on
BioBrick™ standard DNA parts that encode basic biological
functions.”165 Synthetic biologists and biological engineers can
combine BioBricks inside living cells, in a manner analogous to
combining pieces of Lego®, to “program living organisms in the

159. Id.
160. International
HapMap
Project,
Data
Release
Policy,
http://hapmap.ncbi.nlm.nih.gov/datareleasepolicy.html.en (last visited Jan. 15,
2010).
161. Stephen M. Maurer et al., Finding Cures for Tropical Diseases: Is
Open Source an Answer?, 1 PLOS MED. 183, 183 (2004).
162. Id.
163. Id. at 184.
164. The BioBricks Foundation, supra note 106.
165. Id.

TORRANCE_MACROS_FINAL (DO NOT DELETE)

6/16/2010 2:16 PM

2010] SYNTHESIZING LAW FOR SYNTHETIC BIOLOGY

657

same way a computer scientist can program a computer.”166
The Registry is a repository for BioBricks and technical
information about how to make and use BioBricks, currently
housed at MIT.167 Anyone can contribute BioBricks to the
Registry, but biologists are especially encouraged to ensure
that any BioBricks submitted conform to BBF technical
standards and are accompanied by sufficient information to
enable their efficient and predictable use. The BBF “supports
an open technical standards setting process that is used to
define BioBrick™ standard biological parts, and other technical
matters relevant to synthetic biology research and
applications.”168
Open synthetic biology represents a confluence of ideas
from the open source software and open source biology
movements, as well as the fields of biology, synthetic chemistry,
engineering, and computer science. What makes it practicable
is the distinctive chemical basis of heredity: genes. Genes are
composed of deoxyribonucleic acid (“DNA”), a linear chain of
deoxyribonucleotides (“nucleotides”) consisting of adenine (“A”),
thymine (“T”), guanine (“G”), and cytosine (“C”). Genes are
somewhat analogous to software algorithms. Their linear
patterns of As, Ts, Gs, and Cs encode corresponding linear
arrays of ribonucleotides. Some ribonucleotides perform direct
metabolic functions within a cell, while most further encode
linear arrays of amino acids, called polypeptides. Depending
upon their particular nucleotide sequences, polypeptides may
perform structural, signaling, or enzymatic functions within
and between cells. Combinations of genes may encode groups of
polypeptides that perform complicated functions, such as
controlling cell division, immune response, or metabolic
pathways. Although the understanding of gene function is still
in its infancy, most biologists assume that combinations of
genes are also responsible, at least in part, for highly complex
phenomena that take place at the level of the organism, such as
locomotion, hibernation, reproduction, and behavior.
Genes may be identified, characterized, isolated, and
replicated. Their nucleotide sequences and genomic locations
can be deliberately altered, or even inserted into novel host

166. Id.
167. Id.
168. Id.
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cells. Significantly, genes and chromosomes may also be
designed from scratch, and then synthetically manufactured in
large quantities. Just as a supplier of open source software
might make its software easily available to anyone requesting
it, the Registry makes BioBricks easily available to those
conducting biological research or competing in the iGEM
competition.169 And, as with open source software, the
expectation is that those receiving BioBricks may further
modify them structurally, or use arrays of BioBricks to achieve
novel biological structures or functions, and then resubmit such
modifications back into the Registry.
D. A CONSTITUTIONAL LICENSE FOR SYNTHETIC BIOLOGY
Synthetic biology possesses a distinctively democratic
character. From its foundation as a field, a core of influential
synthetic biologists, notably Drew Endy, Tom Knight, and
Randy Rettberg, as well as prominent institutions, such as the
BBF, the Registry, and the iGEM competition, have been
dedicated to ensuring that synthetic biology maintains its
fundamentally open character. Each of the three stated goals of
the BBF reflects this “open-source ethic:”170 (1) “to develop and
implement legal strategies to ensure that BioBrick™ standard
biological parts remain freely available to the public,”; (2) “to
support the development of open technical standards that
define BioBrick standard biological parts,” and (3) “to develop
and provide educational and scientific materials to allow the
public to use and improve existing BioBrick™ standard
biological parts, and contribute new BioBrick™ standard
biological parts.”171
By supporting open technical standards and open standard
setting, the BBF has attempted to define standards for
BioBricks that others would follow. In fact, the tremendous
success the BBF has experienced in amassing BioBricks in the
Registry—more than 5,000 currently available for order by
iGEM competition teams and academic laboratories172—has
made the BBF influential on the rest of synthetic biology.

169. iGEM
2007
Wiki
Main
Page,
http://parts.mit.edu/igem07/index.php/Main_Page (last visited Feb. 2, 2010).
170. Mooallem, supra note 1, at 45.
171. The BioBricks Foundation, supra note 106.
172. Registry, supra note 8.
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There already exists a significant incentive for synthetic
biologists to design their own DNA sequences to comply with
BBF technical standards to ensure interoperability with the
largest possible set of other DNA sequences. Network effects
could drive the widespread, or even universal, adoption of BBF
standards.
Discouraging intellectual property protection for new
BioBricks is more difficult. Some fear that excessive patenting
of DNA sequences could act to discourage, or even stifle,
biological research through what Eisenberg and Heller have
called a “tragedy of the anticommons.”173 The experience of
patents claiming human genes is often cited as a cautionary
tale. Approximately twenty percent of all human genes were
claimed in issued U.S. patents by 2005.174 Widespread
patenting of human genes was described by some as a “gold
rush.”175 Although empirical evidence has, thus far, cast doubt
on the existence of a tragedy of the anticommons caused by
human gene patents,176 proponents of open synthetic biology
worry that their burgeoning field might be especially
vulnerable to excessive patenting. Furthermore, as suggested
earlier, synthetic DNA sequences may be especially easy to
patent or copyright.177
In an effort to manage challenges to synthetic biology
posed by intellectual property, as well as to address other
issues, such as biosafety, attribution, standards, and liability,
the BBF has proposed The BioBrick™ Public Agreement,
Version 1a (the “BioBrick Agreement”).178 The draft agreement,
comprised of both The BioBrick™ Contributor Agreement
(“Contributor Agreement”) and The BioBrick™ User
Agreement (“User Agreement”), has been publicly posted on the
BBF’s website in hopes of attracting support, comments, and
suggestions.
173. Heller & Eisenberg, supra note 140, at 698–701.
174. Kyle Jensen & Fiona Murray, Intellectual Property Landscape of the
Human Genome, 310 SCI. 239, 239 (2005).
175. Tom Hollon, Gene Patent Revisions to Remove Some Controversies, 6
NATURE MED. 362, 362 (2000).
176. Christopher M. Holman, The Impact of Human Gene Patents on
Innovation and Access: A Survey of Human Gene Patent Litigation, 76 UMKC
L. REV. 295, 353–54 (2007).
177. See supra Part III.A, III.B.
178. See infra Part VI; for a copy of the Agreement, see
http://hdl.handle.net/1721.1/50999 (last visited May 12, 2010).
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The first sentence in the Preface of both the Contributor
and User Agreements begins with a broad statement of BBF’s
mission and values:
[The BBF] was established [1] to foster and advance innovation,
research, standardization, and education in synthetic biology [2]
through the open design, construction, distribution, understanding,
and use of BioBrick™ compatible parts, namely standardized genetic
materials and associated functional information, [3] in ways that
benefit the world.179

The Preface identifies three significant goals of the BBF.
The first goal is to promote the development of the synthetic
biology as a field. The word “standardization” signals the
influence of an engineering approach, and a desire to avoid the
messiness and unpredictability of traditional biological science.
The second goal signals that, not only does the BBF
promote the development of synthetic biology as a field of
scientific endeavor, such development should adhere to
principles of openness at every stage of development. Moreover,
the adjective “open,” by modifying all of “design, construction,
distribution, understanding, and use,” implies opposition to
“closed” intellectual property protection.180 The Contributor and
User Agreements both attempt to minimize the threats that
patents and other forms of intellectual property might pose to
achieving and maintaining an open model of synthetic biology.
Section Three of the Contributor Agreement requires
contributors not to assert any intellectual property rights they
may have in BioBricks they contribute against the BBF or
users. Thus, contributors provide assurance that users will
have freedom to use contributed BioBricks. In Section Four,
contributors must specifically identify any intellectual property
rights that pertain to any BioBricks they contribute belonging
to them or to third parties. The User Agreement contains a
complementary Section Two, which requires users to
acknowledge their awareness of contributors’ obligations under
179. See infra Part VI, The BioBrick™ Public Agreement v1a, Preface.
180. However, note that the Preface later recognizes the possibility that
some BioBricks may be encumbered by patent rights. The Contributor
Agreement states: “Some such genetic materials may be subject to patents;
some will not be. The patent-related provisions in this Contributor Agreement
may or may not apply to the Materials” and the User Agreement states: “Some
such genetic materials may be subject to patents; some will not be. The patentrelated provisions in this User Agreement may or may not apply to the
Materials (as defined by one or more Contributors in their respective
Contributor Agreements).”
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Sections Three and Four of the Contributor Agreement.
Consistent with the BBF’s ethos of openness, these provisions
favor the use of full disclosure of information in light of the
possible existence of patent rights relevant to the use of
BioBricks. The full disclosure approach followed by the
BioBrick Agreement raises two important issues. First, it is not
obvious what incentives contributors would have to contribute
their BioBricks, especially if they must effectively relinquish
any intellectual property rights they may have in order to do
so. Second, the BBF will have to decide how to proceed if third
party intellectual property rights encumber a contributed
BioBrick. Possible responses include not accepting the
BioBrick, accepting the BioBrick but refusing to provide it to
users, or simply assuming the risk that providing the BioBrick
to users might trigger indirect infringement of any associated
intellectual property rights. Although the BioBrick Agreement
focuses on the use and contribution of BioBricks, the influence
wielded by the BBF as the predominant—perhaps even
dominant—source of synthetic biological building blocks has
the potential to extend far beyond BioBricks per se. The use of
“BioBrick™ compatible parts” in the BioBrick Agreement,
rather than the logically more restrictive “BioBrick™ standard
DNA parts” commonly used on the BBF website, further
signals the ethos of openness that suffuses the BioBrick
Agreement.
The third goal flows from the modifying statement “in ways
that benefit the world.”181 Concerns about biosafety surround
not only the technologies being developed by synthetic biology
but also the ethos of openness that pervades the field.
Nightmare scenarios include “the malicious use of DNA
sequences posted on the Internet to engineer a new virus or
more devastating biological weapons.”182 Endy has noted that
gene synthesis technology has already enabled the resurrection
of the devastating 1918 influenza virus and could be used to
produce genes of other dangerous pathogens.183 Whereas
previous biotechnological advances have often been perceived
as either subject to proprietary restrictions, or inaccessible to
members of the public lacking requisite academic credentials or

181. See infra Part VI, The BioBrick™ Public Agreement v1a, Preface.
182. Mooallem, supra note 1, at 45.
183. Endy, supra note 2, at 452.
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access to expensive and secure laboratories, the openness of
synthetic biology signals a democratization of access to its
powerful technologies. Critics may worry that open access will
not distinguish between beneficial and malicious users, and
will thereby create the potential for biotechnological mischief
by criminals, terrorists, hostile countries, or even careless
biohackers. The Preface signals that only beneficial uses should
be made of synthetic biology, though the very need to state this
positive value indicates an awareness of its opposite. Section
Seven of the Contributor Agreement and Section Four of the
User Agreement both indirectly address biosafety by requiring
that parties to the agreements comply with the laws in their
jurisdiction. Obviously, such compliance is required regardless
of the BioBrick Agreement. Section Five of the User
Agreement, however, expressly requires users to “refrain from
using the [BioBricks] in connection with any intentionally
harmful, negligent, or unsafe uses.”
The approach to biosafety taken by synthetic biology marks
something of a departure from previous approaches the
biological sciences have taken to manage risk and the
perception of risk. Rather than restricting the technology to
well-credentialed, institutionally-based scientists working in
restricted-access laboratories, the ethos of synthetic biology
demands a more open, democratic, and transparent approach.
The BBF distributes kits of BioBricks to teams of
undergraduates from all over the world. It encourages users to
modify and combine BioBricks in novel ways, and then to share
these modifications with the wider biological community. This
spirit is more akin to computer hacker culture than to
traditional biology. However, “[w]hat’s available to idealistic
students, of course, would also be open to terrorists.”184 The
BioBricks Agreement represents an attempt to address
concerns
about
biosafety
through
contract,
while
simultaneously encouraging a degree of open access. Such an
approach is sure to engender criticism from those who fear the
results of disseminating synthetic biological knowledge and
materials; these concerns will likely grow in response to
technical progress in this promising field of biology. However, a
contrasting perspective doubts the feasibility of successfully
restricting access to a technology as powerful, attractive, and
184. Specter, supra note 20, at 64.
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easy to engage in—even at home using inexpensive
equipment185—as synthetic biology, and, instead, views
openness as an advantage because it could provide a
distributed network of many practitioners bound to notice and
report malfeasance.
A few additional aspects of the BioBrick Agreement are
worth noting. Section Two of the Contributor Agreement
requires contributors to agree to let the BBF insert a
“BioBrick™ Identification Tag” into the DNA sequence of any
contributed BioBrick. Users must make related promises in
Section Three of the User Agreement, agreeing not to remove
any “BioBrick™ Identification Tag” from a BioBrick and to
ensure that the BioBrick Agreement logo is displayed
prominently whenever a BioBrick, or modification thereof, is
made available, commercialized, or distributed; Section Five of
the Contributor Agreement informs contributors of this user
obligation. This trademark policing is intended to ensure that
BioBricks remain both standardized, compatible, and
accessible. Finally, the BioBrick Agreement provides for
attribution. Section Five of the Contributor Agreement allows
contributors to request that users attribute BioBricks to their
contributors when those users describe those BioBricks. Section
Three of the User Agreement requires that users promise to
make such attributions to contributors.
The BioBrick Agreement may be viewed simply as a license
agreement. By defining the obligations of contributors and
users, it attempts to avoid ex ante disputes arising over
ownership, intellectual property rights, attribution, and
liability. Minimizing legal uncertainty may promote the growth
of the Registry and the use of BioBricks. Like the open source
and free software licenses that inspired it, however, the
BioBrick Agreement may also be viewed in a more expansive
light. Rather than a mere license, the BioBrick Agreement may
be viewed as reflecting an initial effort to draft a legal
constitution to guide the beneficial development of the field of
synthetic biology. As with many other constitutions, the
Preface articulates a number of value-laden, interpretive
principles unnecessary to a mere license governing behavior

185. Jeanne Whelan, In Attics and Closets, ‘Biohackers’ Discover Their
Inner Frankenstein: Using Mail-Order DNA and Iguana Heaters, Hobbyists
Brew New Life Forms; Is It Risky?, WALL ST. J., May 12, 2009, at 1.
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between two private actors. These principles—technological
progress, openness, and beneficial uses—may represent the
constitutional values of a field that aspires to more than
efficient contracting and legal compliance. As Michael Specter
recently suggested, “[t]he industrial age is drawing to a close,
eventually to be replaced by an era of biological engineering.”186
If synthetic biology realizes even a fraction of its potential, a
clear articulation of constitutional values may prove much
more valuable to development of the field than a license.

186. Id. at 65.
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V. CONCLUSIONS
Synthetic biology aims to effect a paradigm shift in the
biological sciences. If it is successful in importing engineering
principles, such as standardization, decoupling, and
abstraction, into the biological sciences, it may transform
biology into a field in which it is routine to design and construct
genes, proteins, metabolic pathways, cells, and whole
organisms rapidly, inexpensively, and easily. Already, a
number of institutions have helped synthetic biology achieve
considerable success. The BBF and the Registry have
successfully built a collection of thousands of BioBricks, and
the iGEM competition has attracted participation from
thousands of contestants, hundreds of teams, and dozens of
countries. While the ethos of openness that pervades synthetic
biology promises a democratization of biology, significant
challenges to its openness still exist. The proprietary
restrictions imposed by “closed” intellectual property create
legal risk and uncertainty. Ironically, synthetic DNA sequences
are likely more easily patentable and copyrightable than are
DNA sequences derived from natural sources, thus creating the
possibility that synthetic biology may increase, rather than
decrease, intellectual property restrictions. Furthermore,
concerns about biosafety may be exacerbated by open access to
the products and methods of synthetic biology. To this end, the
BBF has produced the BioBrick Agreement, a licensing
framework intended to govern the legal relationships between
the BBF, BioBricks contributors, and BioBricks users. The
BioBrick Agreement has the potential to be more than a mere
license. In fact, like a constitution, it could help define some of
the foundational values and principles that synthetic biology
might espouse to ensure that its social contributions prove
beneficial to a degree commensurate with its scientific
potential.

